Login
Divisions and Subsidiaries
Forest Pharmaceuticals
Forest Laboratories Europe
Cerexa, Inc.
Forest Laboratories Canada Inc.
About Forest
Overview
Forest identifies, develops, and delivers therapies that make a meaningful difference in people's lives
Products
Research
News
Investor Center
Overview
Forest is building on a strong track record of commercial achievement to deliver important new medicines and strengthen our therapeutic franchises
Annual Reports
Stock Information
Webcasts &
Presentations
Partnerships
Overview
Forest partners with biotech and pharmaceutical companies to develop and bring promising new medicines to market
Capabilities
Careers
Overview
Joining Forest is an opportunity to become part of a forward-thinking community dedicated to helping improve patients' lives through medicine
Job Search
About Forest
Products
Research
News
Media Resources
Press Release Archive
All Press Releases
Business Development News
Corporate News
Financial News
Product News
R&D News
R&D News
03.04.2008
Microbia and Forest Laboratories Announce Preliminary Results of Linaclotide Phase 2b Studies
02.05.2008
Forest Laboratories, Inc. Announces Positive Results of Memantine Study of Once-Daily Formulation
11.01.2007
UPDATE: Nebivolol Lowers Blood Pressure in African Americans With Stage I-II Hypertension as Demonstrated in a Study Published in the Journal of Clinical Hypertension
10.15.2007
Forest Laboratories, Inc. and Gedeon Richter Announce Results of Phase II-B Study for RGH-188 as a Treatment for Schizophrenia
09.18.2007
Study Results for Aclidinium Bromide, a Novel Anticholinergic, Presented at European Respiratory Society Annual Congress
09.04.2007
Nebivolol Lowers Blood Pressure in Mild-to-Moderate Hypertensive Patients as Demonstrated in a Study Published in the Journal of Clinical Hypertension
05.31.2007
Topline Results of Phase III Study in Acute Ischemic Stroke (Dias-2) Do Not Demonstrate Difference Between Desmoteplase and Placebo
05.22.2007
Forest Laboratories, Inc. and Cypress Bioscience, Inc. Announce Positive Results of Phase III Study for Milnacipran as a Treatment for Fibromyalgia Syndrome
05.21.2007
Data Presented at ASH Demonstrate Nebivolol Lowers Blood Pressure as Long-Term Monotherapy and in Combination Therapy
05.01.2007
Response Submitted to FDA Approvable Letter for Hypertension Compound Nebivolol
« first
‹ previous
…
3
4
5
6
7
8
9
10
11
next ›
last »